Human Resource and Employment Services

Lucas GC

Lucas GC released FY2025 9 Months Earnings on April 20, 2026 (EST), with actual revenue of USD 99.63 M and EPS of USD 1.1713

Lucas GC released FY2025 Q4 earnings on April 20 (EST), actual revenue USD 46.84 M, actual EPS USD -0.2952

Lucas GC released FY2025 Q3 earnings on April 20 (EST), actual revenue USD 46.03 M, actual EPS USD -0.2901

Lucas GC released FY2025 Annual Earnings on April 20 (EST), with actual revenue of USD 146.09 M and EPS of USD 0.569

Lucas GC released FY2025 Q2 earnings on October 31 (EST), actual revenue USD 26.97 M, actual EPS USD 0.7354

Lucas GC released FY2025 Semi-Annual Earnings on October 31 (EST), actual revenue USD 53.6 M, actual EPS USD 1.4615

Lucas GC released FY2025 Q1 earnings on October 31 (EST), actual revenue USD 26.63 M, actual EPS USD 0.7261

Lucas GC Announces Follow-on Offering Pricing

Lucas GC released FY2024 Q3 earnings on March 31 (EST), actual revenue USD 32.66 M, actual EPS USD -0.4932

Lucas GC released FY2024 9 Months earnings on March 31 (EST), actual revenue USD 116.25 M, actual EPS USD 3.2827

Lucas GC released FY2024 Q4 earnings on March 31 (EST), actual revenue USD 31.37 M, actual EPS USD -0.4737

Lucas GC released FY2024 annual earnings on March 31 (EST), actual revenue USD 147.71 M, actual EPS USD 2.7876

Lucas GC released FY2024 Semi-Annual earnings on September 26 (EST), actual revenue USD 83.59 M, actual EPS USD 3.7865

Lucas GC released FY2024 Q2 earnings on September 26 (EST), actual revenue USD 41.66 M, actual EPS USD 1.8871

Lucas GC released FY2024 Q1 earnings on September 26 (EST), actual revenue USD 41.93 M, actual EPS USD 1.8993

Rococo Ltd. Obtains Invention Patent in the Field of Artificial Intelligence

Lucas GC released FY2023 Q3 earnings on April 29 (EST), actual revenue USD 44.78 M, actual EPS USD 0.8491

Lucas GC released FY2023 9 Months Earnings on April 29 (EST), actual revenue USD 160.83 M, actual EPS USD 4.6983

Lucas GC released FY2023 Annual Earnings on April 29 After-Market EST, actual revenue USD 206.68 M, actual EPS USD 5.5804

Lucas GC released FY2023 Q4 earnings on April 29 After-Market EST, actual revenue USD 46.06 M, actual EPS USD 0.8735

Micware

Silexion Therapeutics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Linkage Global

GCL Global

Jupiter Neurosciences

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

HCW Biologics

Arcadia Biosciences

BIYA

LGCL

VCIG

JLHL

In Thursday's after-market session, VCI Global (NASDAQ:VCIG) led the gainers with a 15.0% increase to $1.3, followed by Lucas GC (NASDAQ:LGCL) up 7.22% to $1.93, and Baiya International Group (NASDAQ:BIYA) rising 6.79% to $1.1. On the downside, Julong Holding (NASDAQ:JLHL) saw the largest drop, falling 24.9% to $7.3, while Skycorp Solar Group (NASDAQ:PN) decreased by 10.23% to $2.81. Other notable losers included Lakeside Holding (NASDAQ:LSH) and Rectitude Holdings (NASDAQ:RECT).

benzinga_article

Baiya

Skycorp Solar

VCI Global

Julong

flyExclusive

Byrna Tech

FTC Solar

Lakeside

Rectitude

Founder

Volato

FLYEXCLUSIVE INC C/WTS (TO PUR COM)

FOUNDER HOLD

VOLATO GROUP INC C/WTS 04/12/2028(TO PUR COM)

12 Industrials Stocks Moving In Thursday's After-Market Session

LABU

SBIO

IBBQ

GC Biopharma has received marketing authorization for its varicella vaccine, BARYCELA Inj., from the Guatemalan Ministry of Public Health. This marks the first regulatory clearance for the vaccine in Latin America, enhancing access to immunization in the region. BARYCELA Inj. is notable for being produced through an antibiotic-free process, ensuring a superior safety profile. The vaccine has also been recognized by the WHO for its interchangeability with existing vaccines, facilitating its integration into national immunization programs. GC Biopharma aims to expand its market presence with this approval.

prnewswire

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Crescent Biopharma

GT Biopharma

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

02:23 ETGC Biopharma Receives Marketing Authorization for Varicella Vaccine 'BARYCELA Inj.' in Guatemala

Lucas GC Limited held an extraordinary general meeting on December 5, 2025, where shareholders approved a major increase in authorized share capital from $50,000 to $500,000 and potential share consolidation. Amendments to the company's memorandum and articles of association were also approved, enhancing capital management flexibility and market positioning.

Tip Ranks

Lucas GC Limited Approves Major Share Capital Changes

Lucas GC Limited announced the resignation of CFO Brian Lin, effective December 1, 2025. He will be succeeded by Wallace Wang Leong Lee, who has held leadership roles at BON Natural Life Limited and China SXT Pharmaceuticals, Inc. This transition is expected to bring new strategic insights to the company's financial management. The latest analyst rating on LGCL stock is a Hold with a $2.50 price target.

Lucas GC Limited Announces CFO Transition Effective December 1, 2025

Lucas GC Limited (LGCL) has regained compliance with Nasdaq’s minimum bid price requirement, as confirmed by a Compliance Notice received on November 3, 2025. The company maintained a closing bid price of at least $1.00 for 15 consecutive business days. The latest analyst rating for LGCL is a Hold with a $3.00 price target. Spark’s AI Analyst rates LGCL as Neutral, citing mixed financial performance and bearish technical indicators. Lucas GC Limited is an AI technology-driven PaaS company focused on HR and insurance, with a market cap of $9.35M.

Lucas GC Limited Regains Nasdaq Compliance

Lucas GC shares are trading higher after the company reported H1 2025 financial results.

NBIS

Lucas GC pre-market down 10.37%; Nebius pre-market down 5.51%; PMGC pre-market up 134.36%; Greenwave Tech Solutions pre-market up 111.75%; Aqua Metals pre-market up 94.75%

Price Alert

Nebius

Pre-market hot trades in US stocks: Lucas GC pre-market down 10.37%; Nebius pre-market down 5.51%

Lucas GC(LGCL.US)